American Journal of Transplantation · 2012 · 162 citations · 20 references
MedicineNephrologyPharmacologyClinical PharmacologyKidney TransplantationRenal PharmacotherapyAcute RejectionCorticosteroid Use In TransplantationImmunosuppression In Kidney TransplantationMaintenance ImmunosuppressionTransplant PharmacologyTransplant RejectionAcute Renal Allograft RejectionBasiliximab InductionDe Novo TherapyJanus Kinase Inhibitor TherapyKidney Transplant PharmacotherapyMycophenolic Acid TherapyRenal Function EvaluationSerum Creatinine Assessment
In this Phase 2b study, 331 low-to-moderate risk de novo kidney transplant patients (approximately 60% deceased donors) were randomized to a more intensive (MI) or less intensive (LI) regimen of tofacitinib (CP-690, 550), an oral Janus kinase inhibitor or cyclosporine (CsA). All patients received basiliximab induction, mycophenolic acid and corticosteroids. Primary endpoints were: incidence of biopsy-proven acute rejection (BPAR) with a serum creatinine increase of ≥0.3 mg/dL and ≥20% (clinical BPAR) at Month 6 and measured GFR at Month 12. Similar 6-month incidences of clinical BPAR (11%, 7% and 9%) were observed for MI, LI and CsA. Measured GFRs were higher (p < 0.01) at Month 12 for MI and LI versus CsA (65 mL/min, 65 mL/min vs. 54 mL/min). Fewer (p < 0.05) patients in MI or LI developed chronic allograft nephropathy at Month 12 compared with CsA (25%, 24% vs. 48%). Serious infections developed in 45%, 37% and 25% of patients in MI, LI and CsA, respectively. Anemia, neutropenia and posttransplant lymphoproliferative disorder occurred more frequently in MI and LI compared with CsA. Tofacitinib was equivalent to CsA in preventing acute rejection, was associated with improved renal function and less chronic allograft histological injury, but had side-effects at the doses evaluated.
20
The Natural History of Chronic Allograft Nephropathy
Brian J. Nankivell, Richard Borrows, Caroline Fung et al. · New England Journal of Medicine · 2003 · 1.9K citations · Full text
Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation
Henrik Ekberg, Hélio Tedesco‐Silva, A. Demirbaş et al. · New England Journal of Medicine · 2007 · 1.8K citations · Full text